Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, Inc. (Nasdaq: ALEC) reported significant progress in its third quarter 2021 results, including a net income of $126.6 million, or $1.56 per share, compared to a net loss of $52.7 million in Q3 2020. Collaboration revenue surged to $182.4 million, driven primarily by a $500 million upfront payment from GSK for co-developing neurodegenerative disease treatments. The company has initiated a Phase 2 trial of AL001 in ALS patients and received orphan drug designation for frontotemporal dementia.
Alector (Nasdaq: ALEC) will present at two major conferences: the 14th Clinical Trials on Alzheimer's Disease (CTAD) from November 9-12, 2021, and the Society for Immunotherapy of Cancer's (SITC) annual meeting from November 12-14, 2021. Data shared will include results from the Phase 2 INFRONT-2 study of AL001 for frontotemporal dementia and Phase 1 studies of AL003. Alector will also update on AL009 at SITC. An analyst and investor conference call is set for November 12, 2021, at 4:00 p.m. ET to discuss these findings.
Alector, Inc. (Nasdaq: ALEC) has appointed Dr. Elizabeth (Betsy) A. Garofalo to its Board of Directors. With over 25 years in biopharmaceuticals, Dr. Garofalo brings extensive experience in global clinical development, especially in neurology. She has previously held significant roles at Novartis and Pfizer. Dr. Garofalo emphasized Alector's potential in neurology, particularly with its innovative immuno-neurology approach targeting degenerative diseases like Alzheimer’s and ALS. Her leadership is expected to enhance the company’s clinical programs as they advance into later-stage trials.
Alector (ALEC) has initiated a Phase 2 clinical trial for AL001 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS). This randomized, placebo-controlled study will involve approximately 45 participants who will receive AL001 or placebo intravenously every four weeks. The trial aims to evaluate safety, tolerability, and pharmacodynamics, focusing on progranulin levels. AL001 could potentially elevate brain progranulin levels, offering a neuroprotective effect against TDP-43 aggregation, which is linked to ALS pathology. This study represents a significant step towards developing targeted ALS treatments.
Alector, Inc. (Nasdaq: ALEC) announces organizational changes with Shehnaaz Suliman and Robert Paul stepping down as President and Chief Medical Officer, respectively. Sam Jackson appointed as interim Chief Medical Officer. Suliman and Paul will assist during the transition until year-end. Alector has six clinical studies ongoing for four candidates and plans to introduce new treatments in 2022. The CEO expresses gratitude for their contributions, stating the company is well-positioned for future growth in immuno-neurology.
Alector, a clinical-stage biotechnology company pioneering immuno-neurology, has announced participation in several upcoming virtual investor conferences. Key events include:
- Citi’s 16th Annual Biopharma Virtual Conference: Sept 8 at 11:35 a.m. ET and Sept 9 at 1:25 p.m. ET.
- Wells Fargo Virtual Healthcare Conference: Sept 10 at 2:00 p.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference: Sept 13 at 11:45 a.m. ET.
Webcasts will be available on the Alector website, with replays for 30 days.
Alector (NASDAQ: ALEC) reported its Q2 2021 financial results, highlighting collaboration revenue of $6.6 million, up from $3.2 million year-over-year. The company continues to advance its AL001 program in frontotemporal dementia (FTD-GRN), presenting twelve-month data showing a 47% clinical progression slowdown. Alector and GSK established a global partnership, granting Alector $700 million upfront and up to $1.5 billion in potential milestones. As of June 30, 2021, cash and investments totaled $319.6 million, sufficient for operations into mid-2024.
Alector, Inc. (Nasdaq: ALEC) reported promising outcomes from its Phase 2 INFRONT-2 study of AL001, targeting frontotemporal dementia (FTD) due to progranulin gene mutations. At the Alzheimer’s Association International Conference, data showed that AL001 restored progranulin to normal levels and slowed clinical progression by 47% compared to a matched control group. Safety results indicated a favorable profile with mild adverse effects in a small patient cohort. Alector plans to proceed with a Phase 3 study, further assessing AL001's efficacy and safety in FTD patients.
Alector, Inc. (Nasdaq: ALEC) announced an oral presentation on July 29, 2021, regarding the Phase 2 study of AL001 for frontotemporal dementia with a progranulin mutation, at the 2021 Alzheimer’s Association International Conference. The six- and twelve-month data from the open-label INFRONT-2 study will be discussed by Dr. Robert Paul, CMO. Additionally, two posters will present the AL002 Alzheimer’s disease program, including Phase 1 study results and INVOKE-2 trial design. The conference call will be held at 1:00 p.m. ET to review findings.
Alector and GSK have formed a strategic collaboration to co-develop monoclonal antibodies AL001 and AL101 aimed at treating multiple neurodegenerative diseases. This partnership includes a $700 million upfront payment and up to $1.5 billion in potential milestones. Alector will lead clinical development up to Phase 2, while both companies will share commercialization responsibilities in the U.S., with GSK handling international rights. The collaboration could significantly expand treatment options for conditions like frontotemporal dementia, ALS, Parkinson's, and Alzheimer’s.